Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.41 |
| ▸ | JAK1 | P23458 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 12/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 6/20 | 0.40 |
| ▸ | MAPKAPK3 | Q16644 | 3/20 | 0.40 |
| ▸ | MAPK6 | Q16659 | 3/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 6/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137054 | 0.83 | MAPK1 (0.43) | JAK2JAK1MAPK1MAP2K4MAPKAPK3 | |
| SCHEMBL10240133 | 0.83 | JAK2 (0.58) | JAK2JAK1 | |
| SCHEMBL4407745 | 0.83 | PRKAB2 (0.47) | JAK2JAK1MAPK1MAP2K4MAPKAPK3 | |
| SCHEMBL1145032 | 0.81 | MAP2K4 (0.50) | JAK2JAK1MAPK1MAP2K4MAPKAPK3 | |
| SCHEMBL10242014 | 0.79 | ACACB (0.44) | JAK2JAK1MAPK1MAP2K4MAPKAPK3 | |
| SCHEMBL4400846 | 0.79 | CCNC (0.47) | JAK2JAK1MAPK1MAP2K4MAPKAPK3 | |
| SCHEMBL4400777 | 0.79 | MAP2K4 (0.44) | JAK2JAK1MAPK1MAP2K4MAPKAPK3 | |
| SCHEMBL4397852 | 0.79 | MAP2K4 (0.46) | JAK2JAK1MAPK1MAP2K4MAPKAPK3 | |
| SCHEMBL4149673 | 0.79 | JAK2 (0.40) | JAK2JAK1MAPK1MAP2K4MAPKAPK3 | |
| SCHEMBL23675227 | 0.79 | MAP2K4 (0.54) | JAK2JAK1MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181252-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-8993586-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-8859773-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | JAK2 2676/4885JAK1 3818/4885MAPK1 3158/4885 |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | JAK2 2676/4885JAK1 3818/4885MAPK1 3158/4885 |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | JAK2 2676/4885JAK1 3818/4885MAPK1 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.